Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
Annual review of cancer biology · 2021
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 2 countries.
Thomas JacobDepartment of Biomedical Engineering, Oregon Health &Science University, Portland OR 97201, USA.
Anupriya AgarwalDivision of Hematology and Medical Oncology, The Knight Cancer Institute, Oregon Health &Science University, Portland OR 97239, USA.
Damien Ramunno-JohnsonDepartment of Biomedical Engineering, Oregon Health &Science University, Portland OR 97201, USA.
Thomas O'HareDivision of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, Utah 84112, USA.
Mehmet GönenDepartment of Biomedical Engineering, Oregon Health &Science University, Portland OR 97201, USA.
Jeffrey W TynerDivision of Hematology and Medical Oncology, The Knight Cancer Institute, Oregon Health &Science University, Portland OR 97239, USA.
Brian J DrukerDivision of Hematology and Medical Oncology, The Knight Cancer Institute, Oregon Health &Science University, Portland OR 97239, USA.
Tania Q VuDepartment of Biomedical Engineering, Oregon Health &Science University, Portland OR 97201, USA.
Oregon Health & Science University · USKoç University · TRUniversity of Utah · US
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemiaR01CA178397 · NCI · UNIVERSITY OF UTAH · PI DEININGER, MICHAEL W., O'HARE, THOMAS J. · 2014 to 2018
$2.6M
Neuronal signal transduction in space and time using single quantum dotsR01NS071116 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI VU, TOTHU Q · 2011 to 2015
$1.7M
Pathogenetic Mechanism and Clinical Targeting of CSF3R-Driven CancerR01CA183974 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2014 to 2018
$1.6M
Chronic Myelogenous Leukemia and BCR-ABL SubstratesR37CA065823 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J · 2011 to 2015
$1.5M
ROR1 as a Therapeutic Target in Acute Lymphoblastic LeukemiaR00CA151457 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI TYNER, JEFFREY WALLACE · 2012 to 2014
Many important signaling and regulatory proteins are expressed at low abundance and are difficult to measure in single cells. We report a molecular imaging approach to quantitate protein levels by digitized, discrete counting of nanoparticle-tagged proteins. Digitized protein counting provides ultrasensitive molecular detection of proteins in single cells that surpasses conventional methods of quantitating total diffuse fluorescence, and offers a substantial improvement in protein quantitation. We implement this digitized proteomic approach in an integrated imaging platform, the single cell-quantum dot platform (SC-QDP), to execute sensitive single cell phosphoquantitation in response to multiple drug treatment conditions and using limited primary patient material. The SC-QDP: 1) identified pAKT and pERK phospho-heterogeneity and insensitivity in individual leukemia cells treated with a multi-drug panel of FDA-approved kinase inhibitors, and 2) revealed subpopulations of drug-insensitive CD34+ stem cells with high pCRKL and pSTAT5 signaling in chronic myeloid leukemia patient blood samples. This ultrasensitive digitized protein detection approach is valuable for uncovering subtle but important differences in signaling, drug insensitivity, and other key cellular processes amongst single cells.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. · full record | OpenQuestion